DBV Technologies — Third Quarter 2026 Earnings Summary

DBV Technologies submitted a Biologics License Application to the U.S. FDA for its VIASKIN Peanut Patch in children aged 4 to 7 years and requested Priority Review. The company reported a net loss of $64.5 million for the third quarter of 2026, with cash and cash equivalents totaling $165.7 million as of September 30, 2026, which is projected to fund operations into the third quarter of 2027. Despite this runway, management identified substantial doubt regarding the company's ability to continue as a going concern within the next twelve months due to anticipated operating losses and the need for additional capital. Concurrently, DBV is advancing commercial readiness activities and addressing manufacturing remediation efforts with its contract manufacturer, Fareva, ahead of potential Pre-Approval Inspections.